IRIS
DEL PRINCIPE, MARIA ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 31.329
EU - Europa 3.387
AS - Asia 1.808
SA - Sud America 35
OC - Oceania 19
AF - Africa 13
Continente sconosciuto - Info sul continente non disponibili 12
Totale 36.603
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 31.290
SG - Singapore 923
IT - Italia 815
DE - Germania 683
IE - Irlanda 484
CN - Cina 482
UA - Ucraina 428
RU - Federazione Russa 292
GB - Regno Unito 199
KR - Corea 183
FR - Francia 124
FI - Finlandia 118
SE - Svezia 88
NL - Olanda 38
ID - Indonesia 35
CA - Canada 31
PL - Polonia 28
IN - India 25
BE - Belgio 23
PH - Filippine 19
AU - Australia 17
HK - Hong Kong 17
JP - Giappone 17
AT - Austria 15
UZ - Uzbekistan 14
IR - Iran 13
BR - Brasile 12
TH - Thailandia 12
ES - Italia 11
VN - Vietnam 11
PK - Pakistan 10
CZ - Repubblica Ceca 9
TR - Turchia 8
EU - Europa 7
AR - Argentina 6
CL - Cile 6
MX - Messico 6
MY - Malesia 6
PE - Perù 6
SA - Arabia Saudita 6
A2 - ???statistics.table.value.countryCode.A2??? 5
IL - Israele 5
TW - Taiwan 5
BD - Bangladesh 4
CO - Colombia 4
EG - Egitto 4
NO - Norvegia 4
RO - Romania 4
HR - Croazia 3
LB - Libano 3
LT - Lituania 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
ZA - Sudafrica 3
AL - Albania 2
AZ - Azerbaigian 2
CH - Svizzera 2
GR - Grecia 2
IQ - Iraq 2
MA - Marocco 2
NZ - Nuova Zelanda 2
QA - Qatar 2
RS - Serbia 2
BJ - Benin 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
EC - Ecuador 1
GE - Georgia 1
HU - Ungheria 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MN - Mongolia 1
SD - Sudan 1
SN - Senegal 1
TN - Tunisia 1
Totale 36.603
Salva come PNG Salva come JPEG
Città #
Woodbridge 9.113
Wilmington 8.873
Houston 5.144
Fairfield 1.320
Chandler 975
Singapore 808
Ann Arbor 731
Ashburn 673
Seattle 532
Cambridge 464
Dublin 404
Jacksonville 351
Rome 290
Dearborn 288
Medford 288
New York 264
Santa Clara 233
Beijing 192
Lawrence 135
Zhengzhou 100
Boardman 95
San Diego 71
Milan 56
Moscow 56
Mülheim 52
Menlo Park 47
Creede 43
Engelhard 33
Jakarta 32
Bologna 29
Seoul 28
Shanghai 27
London 26
Redwood City 26
Helsinki 23
Brussels 22
Hefei 21
Palo Alto 21
Norwalk 20
Toronto 19
University Park 17
Center 16
Lappeenranta 16
Guangzhou 15
Frankfurt am Main 14
Los Angeles 14
Nanjing 14
Falls Church 13
Kraków 13
Kunming 13
Verona 12
Bang Bai Mai 11
Munich 11
Redmond 11
Turin 11
Kilburn 10
Manila 10
Saint Petersburg 10
Dong Ket 9
Nuremberg 9
Nürnberg 9
Phoenix 9
Bari 8
Brno 8
Florence 8
Hounslow 8
Naples 8
Tokyo 8
Chiswick 7
Groningen 7
Hangzhou 7
Innsbruck 7
Mountain View 7
Pune 7
Roebling 7
Jinan 6
Kuala Lumpur 6
Lima 6
Renton 6
Warsaw 6
Amsterdam 5
Changsha 5
Diyarbakır 5
Islington 5
Mumbai 5
Nanchang 5
Padova 5
Pontedera 5
Prescot 5
San Francisco 5
Shenzhen 5
São Paulo 5
Auburn Hills 4
Bari Sardo 4
Birmingham 4
Buenos Aires 4
Clearwater 4
Colorado Springs 4
Indiana 4
Jeddah 4
Totale 32.411
Salva come PNG Salva come JPEG
Nome #
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 555
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 477
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 452
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 440
Clinical significance of CD38 expression in chronic lymphocytic leukemia 437
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 426
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 425
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 416
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 412
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 411
Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study 408
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 406
Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports 401
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 390
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 388
Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23(+)/MLL+ translocation in leukaemia 386
Advances in the treatment of elderly and frail patients with acute myeloid leukemia 386
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 386
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 384
ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations 384
A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia 383
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 382
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 382
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 381
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey 381
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 380
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 376
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 374
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 373
Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells 373
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study 368
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia 364
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow 363
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 361
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 361
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia 358
Monitoring of minimal residual disease in acute myeloid leukemia 357
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 357
Circulating regulatory T cells in clinical monoclonal B-cell lymphocytosis. 355
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 352
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma 351
Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia 349
Treatment of low-blast count AML using hypomethylating agents 348
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. 347
The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells 344
Extensive toxic epidermal necrolysis following brentuximab vedotin administration 344
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 343
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 342
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features 340
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy 340
Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts 340
Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia 336
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 336
Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia [4] 335
Minimal Residual Disease as Biomarker for Optimal Biologic Dosing of ARA-C in Patients with Acute Myeloid Leukemia 334
Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia 333
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. 329
Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia 328
A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature 328
Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia 326
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia 326
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 326
Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia 322
Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. 316
Longitudinal detection of DNMT3AR882Htranscripts in patients with acute myeloid leukemia 316
Thrombosis in adult patients with acute leukemia 315
Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration? 311
Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia 311
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia 310
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia 309
Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. 308
Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy 307
Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis 305
CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias 303
Risk allocation of adults patients with non-M3 acute myeloid leukemia 299
Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. 298
Apoptosis and immaturity in acute myeloid leukemia 296
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient 290
Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes 288
Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology? 287
CD69 is independently prognostic in chronic lymphocytic leukemia: acomprehensive clinical and biological profiling study 286
Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling 275
In vitro elimination of EGFR-overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitumumab 273
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 266
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study 259
FCγ chimeric receptor-engineered T cells: Methodology, advantages, limitations, and clinical relevance 257
The emerging role of measurable residual disease detection in AML in morphologic remission 249
Fludarabine, Cytarabine and Gentuzumab Ozogamicin (FLA-GO) as Salvage Therapy and Bridge to Transplant in Adult Relapsed Acute Myeloid Leukemia (AML) Patients 247
Gemtuzumab ozogamicin in combination with intensive chemotherapy for relapsed/refractory acute myeloid leukemia 241
Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the campus all network 240
Real-life analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 235
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse 226
An evaluation of enasidenib for the treatment of acute myeloid leukemia 188
Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases 179
Rhodotorula infection in haematological patient: Risk factors and outcome 176
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness 174
Central nervous system fungal infections in allogeneic stem cell transplantation. Outcome of 24 recent cases and literature review 172
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment 160
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab 152
Applications and efficiency of flow cytometry for leukemia diagnostics 148
Totale 33.070
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.828
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.828
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.236 0 0 0 0 0 915 837 845 786 739 508 606
2020/20215.719 638 625 618 758 589 548 718 554 166 196 233 76
2021/20221.672 62 172 46 48 33 171 100 113 139 165 92 531
2022/20232.622 286 230 230 261 157 472 301 163 285 46 134 57
2023/20241.224 104 52 135 36 99 333 57 83 43 31 35 216
2024/20252.079 182 895 532 246 86 138 0 0 0 0 0 0
Totale 37.288